Ceregene Lands $11,500,000 Series D Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    9381 Judicial Drive San Diego, CA 92121
  • Company Description
    Using gene therapy delivery systems, Ceregene’s primary focus is the discovery and development of novel genetic therapeutics for the treatment of neurological disorders. Ceregene aims to be the leader in the field of Central Nervous System (CNS) disease treatment using molecular medicine, an area of great unmet medical need.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series D
  • Proceeds Purposes
    The funds will be used to help support Ceregene’s currently enrolling Phase 2b clinical study of CERE-120 for the treatment of Parkinson’s disease.
  • M&A Terms
  • Venture Investor
    Hamilton BioVentures
  • Venture Investor
    Alta Partners
  • Venture Investor
    MPM Capital
  • Venture Investor
    Investor Growth Capital